APA Alıntı

Tóth, G., Szöőr, Á., Simon, L., Yarden, Y., Szöllősi, J., & Vereb, G. (2016). The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity. MAbs.

Chicago Stili Alıntı

Tóth, Gábor, Árpád Szöőr, László Simon, Yosef Yarden, János Szöllősi, ve György Vereb. "The Combination of Trastuzumab and Pertuzumab Administered At Approved Doses May Delay Development of Trastuzumab Resistance By Additively Enhancing Antibody-dependent Cell-mediated Cytotoxicity." MAbs 2016.

MLA Alıntı

Tóth, Gábor, et al. "The Combination of Trastuzumab and Pertuzumab Administered At Approved Doses May Delay Development of Trastuzumab Resistance By Additively Enhancing Antibody-dependent Cell-mediated Cytotoxicity." MAbs 2016.

Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..